Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDV3100 (Enzalutamide) Phase 1/2 in mCRPC
NCT01284920Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Started Nov 2010; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01284920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284920.